您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2020, Vol. 58 ›› Issue (4): 100-104.doi: 10.6040/j.issn.1671-7554.0.2019.1418

• • 上一篇    

抗苗勒管激素与女性自然妊娠能力的关联分析

高任远1,张敬2,刘方方2,李瑞静2,张秀清3,秦莹莹1   

  1. 1.山东大学附属生殖医院生殖内分泌科, 山东 济南 250021;2.山东大学附属生殖医院健康管理部, 山东 济南 250021;3.山东大学附属省立医院, 山东 济南 250021
  • 发布日期:2022-09-27
  • 通讯作者: 张秀清. E-mail:xiuqing132@163.com
  • 基金资助:
    国家重点研发计划项目(2017YFC1001100),山东省医药卫生科技发展计划(2016Ws0367)

Correlation between anti-müllerian hormone and natural reproductive potential in women

GAO Renyuan1, ZHANG Jing2, LIU Fangfang2, LI Ruijing2, ZHANG Xiuqing3, QIN Yingying1   

  1. 1. Department of Reproductive Endocrinology, Center for Reproductive Medicine, Shandong University, Jinan 250021, Shandong, China;
    2. Department of Health Management, Center for Reproductive Medicine, Shandong University, Jinan 250021, Shandong, China;
    3. Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Published:2022-09-27

PDF (PC)

15

摘要： 目的 探讨血清抗苗勒管激素(AMH)与育龄期女性自然妊娠能力的关联性。 方法 收集2016年1月至2018年5月在山东大学附属生殖医院进行健康查体的601例育龄期女性的临床资料。将受试者按年龄分为低龄组(≤35岁,n=292)和高龄组(>35岁,n=309);每组根据AMH水平,进一步分为低AMH(<1.0 ng/mL)、中AMH(1.0~3.5 ng/mL)以及高AMH(>3.5 ng/mL)3个亚组。随访12个月,比较不同年龄组、不同AMH水平女性的自然受孕率。 结果 601名女性中,202例(33.61%)在12个月随访期内获自然妊娠,其中低龄组临床妊娠率为53.42%(156/292)、高龄组为14.89%(46/309)。低龄组:高、中、低 AMH组的临床妊娠率分别为54.97%(94/171)、56.38%(53/94)、33.33%(9/27),差异无统计学意义(P=0.09);AMH水平与低龄女性自然妊娠率无关联。高龄组:高、中、低AMH组临床妊娠率分别为35.71%(15/42)、21.10%(23/109)、5.06%(8/158),高AMH女性的自然妊娠率较中、低AMH组高,差异有统计学意义(P<0.05);ROC曲线显示,AMH对高龄女性的自然妊娠能力具有一定预测价值(AUCAMH=0.74)。 结论 血清AMH水平对高育龄女性的自然妊娠能力具有一定预测价值,但不能作为年轻女性生育潜能的惟一评价指标。

关键词: 抗苗勒管激素, 年龄, 自然妊娠, 生育力

Abstract: Objective To evaluate the relationship between serum level of anti-müllerian hormone(AMH)and natural reproductive potential in women of childbearing age. Methods Clinical data of 601 women who underwent physical examination during Jan. 2016 and May 2018 were collected. The patients were divided into two groups: young age group(≤35 years old, n=292)and advanced age group(>35 years old, n=309). According to the level of AMH, the two group were further divided into three subgroups: low AMH(<1.0 ng/mL), normal AMH(1.0~3.5 ng/mL)and high AMH(>3.5 ng/mL)groups. All women were followed up for 12 months to observe the natural conception 山 东 大 学 学 报 (医 学 版)58卷4期 -高任远,等.抗苗勒管激素与女性自然妊娠能力的关联分析 \=-rate. Results During the follow-up of 12 months, 202(33.61%)participants were pregnant. The clinical pregnancy rate was 53.42%(156/292)in the young age group and 14.89%(46/309)in the advanced age group. In the young age group, the clinical pregnancy rate in high, normal and low AMH subgroups was 54.97%(94/171), 56.38%(53/94)and 33.33%(9/27), respectively, with no significant difference(P=0.09). In the advanced age group, the clinical pregnancy rate in high, normal and low AMH subgroups was 35.71%(15/42), 21.10%(23/109)and 5.06%(8/158), respectively. A strong correlation was observed between AMH and natural conception rate(P<0.05). The ROC curve showed that AMH had certain predictive value for natural reproductive potential in the advanced age group(AUCAMH=0.74). Conclusion Serum level of AMH is a promising predictor for fertility in advanced age women, but not in young women.

Key words: Anti-müllerian hormone, Age, Natural conception, Fertility

中图分类号: 

  • R711.75
[1] 秦莹莹, 张茜蒻. 卵巢早衰的免疫学病因及免疫干预研究进展[J]. 山东大学学报(医学版), 2018, 56(4): 33-37. QIN Yingying, ZHANG Xiruo. Research advances on the immunological pathogenesis and immunotherapy of premature ovarian failure[J]. Journal of Shandong University(Health Science), 2018, 56(4): 33-37.
[2] Broer SL, Broekmans FJ, Laven JS, et al. Anti-müllerian hormone: ovarian reserve testing and its potential clinical implications[J]. Hum Reprod Update, 2014, 20(5): 688-701.
[3] Bertone-Johnson ER, Manson JE, Purdue-Smithe AC, et al. Anti-müllerian hormone levels and incidence of early natural menopause in a prospective study[J]. Hum Reprod, 2018, 33(6): 1175-1182.
[4] Tal R, Seifer DB. Ovarian reserve testing: a users guide[J]. Am J Obstet Gynecol, 2017, 217(2): 129-140.
[5] Dewailly D, Laven J. AMH as the primary marker for fertility[J]. Eur J Endocrinol, 2019, 181(6): D45-D51.
[6] Zarek SM, Mitchell EM, Sjaarda LA, et al. Is anti-müllerian hormone associated with fecundability? Findings from the EAGeR trial[J]. J Clin Endocrinol Metab, 2015, 100(11): 4215-4221.
[7] Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age[J]. JAMA, 2017, 318(14): 1367-1376.
[8] Hagen CP, Vestergaard S, Juul A, et al. Low concentration of circulating anti-müllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study[J]. Fertil Steril, 2012, 98(6): 1602-1608.
[9] Hawkins Bressler L, Steiner A. Anti-müllerian hormone as a predictor of reproductive potential[J]. Curr Opin Endocrinol Diabetes Obes, 2018, 25(6): 385-390.
[10] Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone[J]. Fertil Steril, 2013, 99(7): 1825-1830.
[11] Cui L, Qin Y, Gao X, et al. Anti-müllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause[J]. Fertil Steril, 2015, 105(2): 481-485.
[12] Silberstein T, MacLaughlin DT, Shai I, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology[J]. Hum Reprod, 2006, 21(1): 159-163.
[13] Fanchin R, Mendez Lozano DH, Frydman N, et al. Anti-müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization[J]. J Clin Endocrinol Metab, 2007, 92(5): 1796-1802.
[14] Hansen KR, Hodnett GM, Knowlton N, et al. Correlation of ovarian reserve tests with histologically determined primordial follicle number[J]. Fertil Steril, 2011, 95(1): 170-175.
[15] Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women[J]. Hum Reprod Update, 2014, 20(3):370-385.
[16] Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-müllerian hormone is associated with oocyte quality in stimulated cycles[J]. Hum Reprod, 2006, 21(8): 2022-2026.
[17] 李蓉, 杨蕊, 刘嘉茵. 卵巢低反应诊疗的再思考[J]. 中华生殖与避孕杂志, 2019, 39(9): 695-698. LI Rong, YANG Rui, LIU Jiayin, et al. A reconsideration of diagnosis and treatment of poor ovarian response[J]. Chinese Journal Reprod Uction Contracep tion, 2019, 39(9): 695-698.
[18] Zhang B, Meng Y, Jiang X, et al. IVF outcomes of women with discrepancies between age and serum anti-Müllerian hormone levels[J]. Reprod Biol Endocrinol, 2019, 17(1): 58. doi: 10.1186/s12958-019-0498-3.
[19] 李梅. 高龄女性的卵子和胚胎质量[J]. 山东大学学报(医学版), 2017, 55(1): 16-21. LI Mei. Quality of oocytes and embryos of elder women[J]. Journal of Shandong University(Health Science), 2017, 55(1): 16-21.
[20] Qiao J, Wang ZB, Feng HL, et al. The root of reduced fertility in aged women and possible therapentic options: current status and future perspects[J]. Mol Aspects Med, 2014, 38: 54-85. doi:10.1016/j.mam.2013.06.001.
[21] May-Panloup P, Boucret L, Chao de la Barca JM, et al. Ovarian ageing: the role of mitochondria in oocytes and follicles[J]. Hum Reprod Update, 2016,22(6): 725-743.
[22] Ben-Meir A, Burstein E, Borrego-Alvarez A, et al. Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging[J]. Aging Cell, 2015, 14(5): 887-895.
[23] Al-Edani T, Assou S, Ferrières A, et al. Female aging alters expression of human cumulus cells genes that are essential for oocyte quality[J]. Biomed Res Int, 2014, 2014: 964614. doi: 10.1155/2014/964614.
[24] Grøndahl ML, Yding Andersen C, Bogstad J, et al. Gene expression profiles of single human mature oocytes in relation to age[J]. Hum Reprod, 2010, 25(4): 957-968.
[25] Tatsumi T, Ishida E, Tatsumi K, et al. Advanced paternal age alone does not adversely affect pregnancy or live-birth rates or sperm parameters following intrauterine insemination[J]. Reprod Med Biol, 2018, 17(4): 459-465.
[26] Simon L, Murphy K, Shamsi MB, et al. Paternal influence of sperm DNA integrity on early embryonic development[J]. Hum Reprod, 2014, 29(11): 2402-2412.
[1] 李萍,何雪梅. 女性生育力评估[J]. 山东大学学报 (医学版), 2022, 60(9): 8-11.
[2] 阮祥燕,程姣姣,杜娟,谷牧青. 卵巢组织冷冻保存[J]. 山东大学学报 (医学版), 2022, 60(9): 24-30.
[3] 吴瑞芳,李长忠. 女性生育力保护的现状与进展[J]. 山东大学学报 (医学版), 2022, 60(9): 1-7.
[4] 石玉华,潘烨,谢燕秋. 胚胎冷冻保存技术及进展[J]. 山东大学学报 (医学版), 2022, 60(9): 12-18.
[5] 颜磊,岳彩欣,刘懿淳. 子宫内膜异位症的生育力保护[J]. 山东大学学报 (医学版), 2022, 60(9): 31-34.
[6] 林芸,谢燕秋. 乳腺癌患者生育力保护及保存[J]. 山东大学学报 (医学版), 2022, 60(9): 42-46.
[7] 郝桂敏,罗卓野,王奕卓. 生育力保存的伦理问题及思考[J]. 山东大学学报 (医学版), 2022, 60(9): 47-52.
[8] 吴日超,刘红,王泽,高姗姗,李秀芳,石玉华. 40岁及以上女性行体外受精-胚胎移植助孕的妊娠结局分析[J]. 山东大学学报 (医学版), 2022, 60(6): 35-39.
[9] 朱序理,周亮,王跃,孙庆云,曹明雅,杜元杰,曹金凤,赵志明,郝桂敏. 不同精子来源质量冷冻方式与妊娠结局的关联性分析[J]. 山东大学学报 (医学版), 2021, 59(6): 86-93.
[10] 孙梅,崔文娟. 影响生育力的因素及高龄生育的策略[J]. 山东大学学报 (医学版), 2019, 57(2): 23-28.
[11] 阮祥燕,程姣姣,杜娟,李扬璐,金凤羽,Alfred O. Mueck. 生育力保护方法研究进展[J]. 山东大学学报 (医学版), 2019, 57(2): 29-34.
[12] 师娟子,陈丽娟. 辅助生殖技术进展[J]. 山东大学学报 (医学版), 2019, 57(10): 1-6.
[13] 李小娟,段海霞. 辅助生殖治疗中宫腔镜手术应用及注意问题[J]. 山东大学学报 (医学版), 2019, 57(10): 38-44.
[14] 韩婷,陈红蕾. 辅助生殖治疗中腹腔镜手术应用及注意问题[J]. 山东大学学报 (医学版), 2019, 57(10): 45-51.
[15] 陈士岭,周星宇. 早发性卵巢功能不全的临床诊治进展[J]. 山东大学学报 (医学版), 2018, 56(4): 1-7.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发